ASCO GU 2024

Is "more" always better?

Cabo + IO: Interesting but not practice changing?!

Combination vs. monotherapy - a great new option for high-risk patients

BRCAAway - practice changing or hypothesis generating data?

Relugolix combined with androgen signaling in real word experience

Stockholm3 validated in multiethnic cohort

Combination of cabozantinib & checkpoint inhibitor

Still a difficult time for androgenic inhibitors in mCRPC

Evaluating the recombination-repair mutations in patients with mCRPC

Long-term dose escalation - Therapy in high-risk prostate cancers

Salvage radiation with anti-androgen superior to radiation alone

What about the clinical benefit?

First positive study of IO therapy in mCRPC

Further testing before olaparib combination

Gleason 3+3 - cancer or not?

Cognitive function in ART treatment

Enzalutamide therapy as option for biochemical recurrence

Combination NHT + PARP makes sense

Therapy Intensification Still Neglected in mHSPC

Insights and news for mCRPC

Quality of life under intensive therapy

Olaparib + Arbiraterone better compared to either alone

Localized PCa - news for radiotherapy and biochemical recurrence

Dose de-escalation in different ways

Higher radiation is effective in high-risk PCA

BRCAaway - PARP combination study

Gleason 3+3 ska vi kalla de cancer eller inte?

Kombination av cabozantinib och immunterapi

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi)

Orta riskli PCa da RARP sirasinda LND dan vazgecilebilir mi?

Une période encore difficile pour les inhibiteurs androgéniques dans le cancer de la prostate métastatique résistant à la castration.

Post-RP salvage radyoterapi hormonoterapi ile konbine edilmeli

SEPTA calismasi: Stockholm3 un multietnik hasta grubunda validasyonu

BRCAAway - PARP hämmare, abiraterone eller i kombination

Kognitiv påverkan av abirateron och enzalutamid?

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO GU '24

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

New standard of care, but still open questions!

Advances in (neo)-adjuvant treatment in urothelial cancer

The emerging field of biomarkers in bladder cancer

ADC + ICI: new data for platinum-refractory bladder cancaer patients

Should we start forgetting the Galsky Criteria in advanced urothelial carcinoma?

HER2 and bladder cancer

ASCO GU24 - Highlights in Bladder cancer

Biomarker update

Pembrolizumab adjuvant in bladder cancer

Adjuvant Nivolumab Shows Promise in Boosting Long-Term Survivorship for High-Risk Muscle-Invasive Urothelial Carcinoma

EV + Pembro new first-line standard in localized metastatic bladder cancer

Highlights in bladder cancer at ASCO GU24

Adjuvant therapy in urothelial carcinoma : is the equation resolved?

EV as standard in 3rd line mUC

Update on EV-302

MIBC: adjuvant PD1 - all set?!

Update M1 urothelial cancer

Perioperative adjuvant therapy in urothelial cancer

Another success for an ICI?

Novedades sobre EV-302

Tratamiento adyuvante en cancer urotelial: ¿está resuelta la ecuación?

Encore un succès pour une ICI ?

Terapia adyuvante perioperatoria en el cáncer de vejiga

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

¿Deberíamos empezar a olvidarnos de los Criterios de Galsky en cancer urotelial avanzado?

No surprise with the QoL data

Adjuvant therapy in kidney cancer: Is immunotherapy the answer?

Trial updates at ASCO GU24: Are the follow-up data confirmatory?

Subcutaneous vs. intravenous application: ready for everyday clinics?

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark CheckMate-9ER Trial: Prolonged Efficacy and Safety Reinforce Standard of Care in Advanced Renal Cell Carcinoma

ASCO GU24 - Highlights in renal cell carcinoma

Practice changing adjuvant therapy?!

Long-Term Data on NIVO+IPI in aRCC

Highlights in kidney cancer at ASCO GU24

Long-term outcome

Cabozantinib Plus Atezolizumab in Adrenocortical Carcinoma Falls Short of Expectations, Emphasizing Ongoing Need for Treatment Innovations

Perioperative treatment in renal cell carcinoma - did we close the circle?

Long-term follow-up of first-line trials

Tumorburden and outcome

Durable effects of Ipi-Nivo

Belzutifan: Updates on QoL

Subcutaneous Nivolumab Matches IV Formulation in Clear Cell Renal Cell Carcinoma, Paving the Way for Enhanced Therapy Delivery and Safety

Overall survival benefit - Pembro after surgery

Better QoL with Belzutifan

Tratamiento perioperatorio en cancer renal: ¿Hemos cerrado el círculo?

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24